Highly Effective of Gemcitabine and Cisplatin (GP) as First-Line Combination Therapy in Patients with Triple-Negative Metastatic Breast Cancer: Final Report of a Phase II Trial.

被引：0
|
作者：
Wang, Z. [1 ]
Hu, X. [1 ]
Wang, B. [1 ]
Wang, L. [1 ]
Zhang, J. [1 ]
Wang, H. [1 ]
Liu, G. [1 ]
Hu, Z. [1 ]
Wu, J. [1 ]
Shao, Z. [1 ]
机构：
[1] Fudan Univ, Shanghai Med Coll, Canc Hosp, Shanghai 200433, Peoples R China
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P5-19-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-19-06
引用
收藏
页数：1
相关论文
共 50 条
  • [21] WHETHER CHIDAMIDE IMPROVES THE RESPONSE TO CISPLATIN IN FIRST-LINE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER
    Zhang, Jian
    Hu, Xichun
    Meng, Yanchun
    Jin, Juan
    Gong, Chengcheng
    Miao, Haitao
    Tao, Zhonghua
    Li, Ting
    Cao, Jun
    Wang, Leiping
    Wang, Biyun
    Hu, Xichun
    BREAST, 2021, 59 : S46 - S46
  • [22] Updated survival data and biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Zhang, Jian
    Lin, Ying
    Hu, Xi-Chun
    Yang, Wentao
    Sun, Xiangjie
    Wang, Biyun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] An phase II trial of docetaxel and cisplatin as first-line therapy for anthracycline-naive metastatic breast cancer patients
    Shen, Wen-Chi
    Chang, Hsien-Kun
    Chen, Jen-Shi
    Lin, Yung-Chang
    ANNALS OF ONCOLOGY, 2006, 17 : 86 - 86
  • [24] Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial
    Karthaus, Meinolf
    Poddubnaya, Irina
    Churilova, L.
    Khazanov, R.
    Veremeychuk, T.
    Rumyantzeva, E.
    Garin, M.
    Brichkova, O.
    Heinrich, Bernhard
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracyclinenaive patients with metastatic breast cancer
    Lin, Yung-Chang
    Chang, Hsien-Kun
    Shen, Wen-Chi
    Chen, Jen-Shi
    Wang, Hung-Ming
    ANTI-CANCER DRUGS, 2007, 18 (10) : 1213 - 1219
  • [26] Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma
    Tsao, Che-Kai
    Agarwal, Neeraj
    Apolo, Andrea Borghese
    Lee, Karen M.
    Godbold, James H.
    Oh, William K.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
    Emens, L.
    Adams, S.
    Loi, S.
    Schmid, P.
    Schneeweiss, A.
    Rugo, H.
    Chui, S.
    Winer, E.
    CANCER RESEARCH, 2016, 76
  • [28] Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer
    Chua, Daniel T. T.
    Yiu, Harry Ho-Yin
    Seetalarom, Kasan
    Ng, Alice Wan-Ying
    Kurnianda, Johan
    Shotelersuk, Kanjana
    Krishnan, Gopala
    Hong, Ruey-Long
    Yang, Muh-Hwa
    Wang, Cheng-Hsu
    Sze, Wing-Kin
    Ng, Wai-Tong
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2012, 34 (09): : 1225 - 1230
  • [29] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
    Obeid, E.
    Miller, K. D.
    Sparano, J. A.
    Blackwell, K.
    Goldstein, L. J.
    CANCER RESEARCH, 2017, 77
  • [30] A phase II trial of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer
    Meshref, M. M.
    Samir, S.
    Saad, E.
    Gouda, Y.
    Elmesidy, S.
    Koheil, H.
    Elzawahri, H.
    Kandil, A.
    Abdelhamid, T.
    Zaki, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345